The Ebola outbreak in the eastern Democratic Republic of Congo has grown to more than 1,400 confirmed cases and over 430 deaths, according to World Health Organization figures, making it the third-largest on record and one of the fastest-escalating first months of any Ebola epidemic in Africa. As of June 30, the DRC had recorded 1,406 confirmed cases and 438 deaths, with 609 people hospitalized in isolation and 208 recovered.
The outbreak is concentrated in Ituri province, which accounts for 1,283 cases and 366 deaths across 24 of its 36 health zones, with smaller clusters in North Kivu and South Kivu. Neighboring Uganda has reported 20 cases and two deaths linked to travelers from the DRC, and a single imported case reached France — a reminder of how quickly a regional outbreak can touch distant health systems.
What sets this emergency apart from recent ones is the pathogen. The virus is the Bundibugyo species, a less common member of the Ebola family than the Zaire strain that drove the catastrophic 2014-16 West Africa epidemic and the large 2018-20 outbreak in the same eastern Congo region. That distinction is not academic. The licensed Ervebo vaccine, which anchored those earlier responses, was developed against the Zaire virus, and the WHO has judged the evidence for cross-protection insufficient — so it is advising against deploying Ervebo here, leaving responders without the tool they have come to rely on.
There is no approved vaccine or specific antiviral treatment for Bundibugyo. Three candidate vaccines, backed by IAVI, Moderna and Oxford University, are being advanced with expedited funding, but none is ready for the kind of ring vaccination — inoculating the contacts of each confirmed case — that helped bring past outbreaks under control. In its place, the response falls back on the slower fundamentals: contact tracing, isolation of the sick, safe and dignified burials, and community engagement to counter the fear and rumor that spread as fast as the virus.
The case count itself has been a moving target, and the revisions tell their own story about how hard this outbreak is to track. Early in the emergency, suspected cases far outran confirmed ones; by June 2, retesting had confirmed only about 116 of some 906 suspected infections, prompting the WHO to sharply downsize its running tally. Within three weeks the confirmed total had blown past 1,000 and kept climbing — a trajectory that reflects both genuine spread and a testing system finally catching up to it.
Ituri is among the most difficult places in the world to mount an epidemic response. Armed groups operate across the province, humanitarian access is intermittent, and health workers have repeatedly been forced to suspend operations during past outbreaks when violence flared. The WHO has rated the risk "very high" within the DRC and "high" for Uganda and the wider region, while judging the global risk low. For the communities of Ituri, the arithmetic is simpler and grimmer: without the vaccine that shortened earlier outbreaks, containment depends on doing the basics well, everywhere, at once.